HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

Altimmune Inc

Altimmune Inc

ALT

0.00

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ: ALT) with a Buy and lowers the price target from $25 to $20.